Antagonistic action of a synthetic androgen ligand mediates chromatin remodeling in a human prostate cancer cell line

Androgen receptor (AR) antagonists have been clinically applied with success to the prostate cancer patients and draw remission of androgen-dependent tumors. However, a couple of years after the treatments, transit of the tumors into in androgen-independent state is often observed with altered gene expression profiles, but the molecular basis is barely known. Since the AR antagonists trigger the transition, we tested in the present study if the AR antagonists are potent to induce chromatin reorganization in an androgen-dependent prostate cancer cell line (LNCaP cells). Overall design: Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) by LNCaP cells treated MeOH (control), DHT (10 nM) and bicalutamide (10 µM) for 5 h or 120 h.